Publicly-held clinical-stage biotechnology company (NASDAQ: LRMR) focused on developing treatments for complex rare diseases.

Industry leader of oral fluid diagnostic and collection technologies.

Chief Operating Officer (2018-2019); Chief Financial Officer (2016-2017)): Specialty pharmaceutical company with a high performing revenue generating contract development and manufacturing (CDMO) division.

Private- equity funded consumer products branded heath, wellness and self-care company. Sold in 2016 to Patterson Medical (Madison Dearborn).

Private equity-funded clinical laboratory services company with annualized revenue growth run rate of over 25%. Sold in 2017 to ACM Global Laboratories

Medical device company ($90 million in annual revenues) focused on regenerative medicine utilizing its proprietary collagen and polymer technology. Sold to Royal DSM (DSM) for $38.50 per share, an all time high. During three-year tenure, Kensey Nash transformed itself from a contract manufacturer to a profitable regenerative medicine business. As co-leader of business development efforts, closed on four transactions. In addition, played a key role in the team which settled long-standing license agreement dispute, and extended the manufacturing relationship with a major customer. Partnered with CEO in managing investor relations activities.

Led business development activities in key U.S. markets, focused on product/clinical trial, D&O and enterprise risk management.

Venture-funded life sciences company. Grew from a 20-person start-up with a $35 million valuation to being sold in 2007 to Pfizer in a cash transaction totaling approximately $200 million.

Starting with Arthur Andersen in 1980, spent early career servicing venture-funded, public technology-based companies. Focused on life sciences industry as it grew in the late 1980s, eventually becoming Partner-in-Charge of Andersen’s Life Sciences Practice in the Mid-Atlantic Region in 1994. From 2000 to 2002, co-chaired Andersen’s U.S. Life Sciences Practice. After leaving Andersen, held similar leadership positions with KPMG through 2004. During public accounting career, served more than 40 life science clients, including serving as lead audit partner for 17 public life science companies. Viewed as the most respected auditor of life science companies in the mid-Atlantic region. Built a practice with a Philadelphia region market share of over 50%.